@FiercePharma: ICYMI: This week's issue of FiercePharmaMarketing. Subscribe here, if you please | Follow @FiercePharma
@TracyStaton: Tops @FiercePharma over the weekend: Top Sanofi exec departs amid struggles in diabetes franchise. More | Follow @TracyStaton
@EricPFierce: Instead of buying counterfeit Viagra from China, this guy bought APIs and whipped up an ED drug in his home lab. More | Follow @EricPFierce
@CarlyHFierce: EMA accepts Pfizer app to expand Prevenar in adults. FierceVaccines story | Follow @CarlyHFierce
> The EU has approved Roche's ($RHHBY) Avastin for the hardest-to-treat form ovarian cancer. More
> Amid a 30% second-quarter profit dive, Mylan ($MYL) trimmed its full-year forecast and revenue outlook. Report (sub. req.)
> Walgreen ($WAG) agreed to acquire the remainder of Alliance Boots for about $5.27 billion and will not move its tax base to the U.K. More
> Astellas Pharma's European division has appointed Simon Dew as chief strategy officer and Jun Kono as VP of corporate strategy and communications. More
> Mallinckrodt ($MNK) raised its full-year guidance on narrower losses in Q3. Report
> Daiichi Sankyo and Charleston Laboratories have announced a collaboration to commercialize the latter's hydrocodone products in the U.S. Report
> The FDA has green-lighted Zydus Cadila's Potassium Citrate ER tablets for use in prevention of kidney stones. Report
> The FDA has approved The Medicines Co.'s ($MDCO) acute skin infection drug. Report
Medical Device News
@FierceMedDev: Carnegie Mellon team creates self-assembling nanofibers for shaped delivery vehicles. FierceDrugDelivery story | Follow @FierceMedDev
@StacyALawrence: Ten big med tech companies add 25,000 jobs in 2013. Article | Follow @StacyALawrence
@VarunSaxena2: Stentys ditches bare metal stents as customers move to drug-eluting versions. ICYMI from FierceDrugDelivery | Follow @VarunSaxena2
@MichaelGFierce: Thin and strong, graphene sheets form spheres spontaneously for drug release. More from FierceDrugDelivery | Follow @MichaelGFierce
@EmilyWFierce: Saving Lives at Birth initiative developing innovative devices to improve infant health in underserved communities. More from National Geographic | Follow @EmilyWFierce
> St. Jude Medical seals the deal on NeuroTherm to gain ground in neuromodulation. News
> NeuroPace RNS Stimulator secures add-on payments from CMS. Story
> Alere to complete strategic review by year-end. Article
Biotech News
@FierceBiotech: Daiichi Sankyo bets up to $650M on Charleston's pain potential. Article | Follow @FierceBiotech
@JohnCFierce: ICYMI yesterday: Interesting fact, when DoD stopped $SRPT's work on Ebola, they left in a provision to reactivate the $291M contract. Article | Follow @JohnCFierce
@DamianFierce: RT @FierceBiotech: New special report: The top 15 late-stage blockbusters in the pipeline. Feature | Follow @DamianFierce
> Novo picks up the pace with its next-gen insulin, eyeing a 2016 U.S. debut. More
> Hype and hope compete as overnight stardom engulfs untried Ebola drugs. Report
> After a 6-year delay, Medicines Co. bags FDA approval for once-troubled antibiotic. News
Vaccines News
> Bavarian Nordic the only bidder for Canada's smallpox vax supply. Item
> NIH: Ebola vaccine trial could begin as early as September. Report
> Affiris clears Phase I with Parkinson's vaccine candidate. Story
> U.K. and Novartis begin price negotiations on Bexsero. More
> Sanofi dengue vaccine filings could come as soon as next year's Q1, CEO says. Article
Pharma Manufacturing News
> Alvogen adds Asian manufacturing capacity in $187M Dream Pharma buyout. News
> Impax looking to use $400M cash stash for M&A. Report
> Fresenius awaiting FDA reinspection at plants in NY, India. Story
> Ebola outbreak puts spotlight on tobacco-based drug production. More
> Cubist issues third recall in 12 months after another CMO quality failing. Article
And Finally... Biogenesis founder Anthony Bosch, the man at the center of Major League Baseball's recent performance-enhancing drug scandal, has surrendered to the Drug Enforcement Agency (DEA). Article (sub. req.)